These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2. Uzunova K; Filipova E; Pavlova V; Vekov T Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965 [TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial. Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849 [TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus. Costanzo M; De Giglio MAR; Roviello GN Curr Med Chem; 2020; 27(27):4536-4541. PubMed ID: 32297571 [TBL] [Abstract][Full Text] [Related]
6. Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa: Caution for Inappropriate Off-label Use in Healthcare Settings. Abena PM; Decloedt EH; Bottieau E; Suleman F; Adejumo P; Sam-Agudu NA; Muyembe TamFum JJ; Seydi M; Eholie SP; Mills EJ; Kallay O; Zumla A; Nachega JB Am J Trop Med Hyg; 2020 Jun; 102(6):1184-1188. PubMed ID: 32323646 [TBL] [Abstract][Full Text] [Related]
7. Potential specific therapies in COVID-19. Gul MH; Htun ZM; Shaukat N; Imran M; Khan A Ther Adv Respir Dis; 2020; 14():1753466620926853. PubMed ID: 32436445 [TBL] [Abstract][Full Text] [Related]
8. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research. Bimonte S; Crispo A; Amore A; Celentano E; Cuomo A; Cascella M In Vivo; 2020 Jun; 34(3 Suppl):1597-1602. PubMed ID: 32503817 [TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
10. Clinical Trials of Repurposed Antivirals for SARS-CoV-2. Martinez MA Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826 [TBL] [Abstract][Full Text] [Related]
11. The broad-spectrum antiviral recommendations for drug discovery against COVID-19. Hazafa A; Ur-Rahman K; Haq IU; Jahan N; Mumtaz M; Farman M; Naeem H; Abbas F; Naeem M; Sadiqa S; Bano S Drug Metab Rev; 2020 Aug; 52(3):408-424. PubMed ID: 32546018 [TBL] [Abstract][Full Text] [Related]
12. A global treatments for coronaviruses including COVID-19. Yousefi B; Valizadeh S; Ghaffari H; Vahedi A; Karbalaei M; Eslami M J Cell Physiol; 2020 Dec; 235(12):9133-9142. PubMed ID: 32394467 [TBL] [Abstract][Full Text] [Related]
13. Psychopharmacology of COVID-19. Bilbul M; Paparone P; Kim AM; Mutalik S; Ernst CL Psychosomatics; 2020; 61(5):411-427. PubMed ID: 32425246 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis. Liu W; Zhou P; Chen K; Ye Z; Liu F; Li X; He N; Wu Z; Zhang Q; Gong X; Tang Q; Du X; Ying Y; Xu X; Zhang Y; Liu J; Li Y; Shen N; Couban RJ; Ibrahim QI; Guyatt G; Zhai S CMAJ; 2020 Jul; 192(27):E734-E744. PubMed ID: 32493740 [TBL] [Abstract][Full Text] [Related]
15. Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review. Giovane RA; Rezai S; Cleland E; Henderson CE Rev Med Virol; 2020 Sep; 30(5):e2136. PubMed ID: 32644275 [TBL] [Abstract][Full Text] [Related]
16. Medication therapy strategies for the coronavirus disease 2019 (COVID-19): recent progress and challenges. Yang X; Liu Y; Liu Y; Yang Q; Wu X; Huang X; Liu H; Cai W; Ma G Expert Rev Clin Pharmacol; 2020 Sep; 13(9):957-975. PubMed ID: 32746653 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Hassaniazad M; Bazram A; Hassanipour S; Fathalipour M Trials; 2020 Oct; 21(1):886. PubMed ID: 33109246 [TBL] [Abstract][Full Text] [Related]
18. Some drugs for COVID-19. Med Lett Drugs Ther; 2020 Apr; 62(1595):49-50. PubMed ID: 32324177 [No Abstract] [Full Text] [Related]
19. An Update on Current Therapeutic Drugs Treating COVID-19. Wu R; Wang L; Kuo HD; Shannar A; Peter R; Chou PJ; Li S; Hudlikar R; Liu X; Liu Z; Poiani GJ; Amorosa L; Brunetti L; Kong AN Curr Pharmacol Rep; 2020; 6(3):56-70. PubMed ID: 32395418 [TBL] [Abstract][Full Text] [Related]
20. COVID-19 diagnosis and management: a comprehensive review. Pascarella G; Strumia A; Piliego C; Bruno F; Del Buono R; Costa F; Scarlata S; Agrò FE J Intern Med; 2020 Aug; 288(2):192-206. PubMed ID: 32348588 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]